| Identification | Back Directory | [Name]
4-Pyridinecarboxamide, 2-(4-methyl-1-piperazinyl)-N-[6-(1-methyl-1H-pyrazol-4-yl)-3-isoquinolinyl]- | [CAS]
2143917-62-6 | [Synonyms]
SM08502
Cirtuvivint
Cirtuvivint( SM08502)
Cirtuvivint (Synonyms: SM08502)
4-Pyridinecarboxamide, 2-(4-methyl-1-piperazinyl)-N-[6-(1-methyl-1H-pyrazol-4-yl)-3-isoquinolinyl]- | [Molecular Formula]
C24H25N7O | [MOL File]
2143917-62-6.mol | [Molecular Weight]
427.5 |
| Chemical Properties | Back Directory | [storage temp. ]
4°C, away from moisture and light | [solubility ]
DMSO : 12.5 mg/mL (29.24 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research[1]. | [in vivo]
Orally administered Cirtuvivint (SM08502) significantly inhibits growth of gastrointestinal tumors and decreased SRSF phosphorylation and Wnt pathway gene expression in xenograft mouse models[1]. | [storage]
4°C, away from moisture and light | [References]
[1] Betty Y Tam, et al. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models. Cancer Lett. 2020 Mar 31;473:186-197. DOI:10.1016/j.canlet.2019.09.009 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|